<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47360/1995-4484-2022-519-525</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-3216</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПРОГРЕСС В РЕВМАТОЛОГИИ В XXI ВЕКЕ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PROGRESS IN RHEUMATOLOGY IN THE XXI CENTURY</subject></subj-group></article-categories><title-group><article-title>Патофизиология метаболизма железа и гепсидин: перспективы изучения в ревматологии</article-title><trans-title-group xml:lang="en"><trans-title>Pathophysiology of iron and hepcidin metabolism: research perspectives in rheumatolog</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6068-3080</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лила</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lila</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лила А.М. – директор, член-корреспондент РАН, дмн, профессор</p><p>115522, Москва, Каширское шоссе, 34а; 125993, Москва, ул. Баррикадная, 2/1, стр. 1</p></bio><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A; 125993,  Moscow, Barrikadnaya str., 2/1, building 1</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2776-4276</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Галушко</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Galushko</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Галушко Е.А. – ведущий научный сотрудник лаборатории эволюции ревматоидного артрита., дмн</p><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Семашко</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Semashko</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Семашко А.С. – аспирантка 2 года обучения </p><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><email xlink:type="simple">annsemashko@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology;&#13;
Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>10</day><month>11</month><year>2022</year></pub-date><volume>60</volume><issue>5</issue><fpage>519</fpage><lpage>525</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лила А.М., Галушко Е.А., Семашко А.С., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Лила А.М., Галушко Е.А., Семашко А.С.</copyright-holder><copyright-holder xml:lang="en">Lila A.M., Galushko E.A., Semashko A.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/3216">https://rsp.mediar-press.net/rsp/article/view/3216</self-uri><abstract><p>Несмотря на прогресс в изучении метаболизма железа, анемия хронического воспаления (АХВ) и дефицит железа по-прежнему остаются серьезными глобальными проблемами здравоохранения. При иммуновоспалительных ревматических заболеваниях (РЗ) наиболее частыми их вариантами являются железодефицитная анемия (ЖДА) как наиболее распространенный тип анемии, и АХВ, которая сама по себе может утяжелять течение основного заболевания за счет перегрузки железом тканей, дополнительной активации и поддержания активности воспаления. В течение последних лет широко обсуждается диагностическая и терапевтическая роль гепсидина как ключевого регулятора метаболизма железа. Изучение путей регуляции и синтеза гепсидина при иммуновоспалительных РЗ может иметь немаловажное значение для выявления патогенетических механизмов, лежащих в основе формирования резистентности к проводимой терапии, а также к появлению у пациентов тяжелой сопутствующей патологии, затрудняющей назначение адекватной терапии. Наиболее интересными с точки зрения перспективы дальнейшего изучения являются ось интерлейкин 6 – JAK2 – STAT3 и хроническая гипоксия, которая встречается при таких хронических состояниях, как сердечно-сосудистая патология, хроническая болезнь почек, интерстициальное поражение легких и др.</p></abstract><trans-abstract xml:lang="en"><p>Despite advances in the study of iron metabolism, anemia of chronic inflammation (AI) and iron deficiency remain major global health problems. In immunoinflammatory rheumatic diseases (RD), the most common variants are iron deficiency anemia (IDA) as the most common type of anemia, and AI, which itself can aggravate the course of the underlying disease due to tissue iron overload, additional activation and maintenance of inflammation activity. In recent years, the diagnostic and therapeutic role of hepcidin as a key regulator of iron metabolism has been widely discussed.</p><p>The study of the ways of regulation and synthesis of hepcidin in immuno-inflammatory RD may be of great importance for identifying the pathogenetic mechanisms underlying the formation of resistance to therapy, as well as for the appearance of severe concomitant pathology in patients that makes it difficult to prescribe adequate therapy. The most interesting from the perspective of further study are the interleukin 6 – JAK2 – STAT3 axis and chronic hypoxia, which occurs in such chronic conditions as cardiovascular pathology, chronic kidney disease, interstitial lung damage, etc.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ревматоидный артрит</kwd><kwd>метаболизм железа</kwd><kwd>гепсидин</kwd><kwd>интерлейкин 6</kwd></kwd-group><kwd-group xml:lang="en"><kwd>arthritis</kwd><kwd>iron metabolism</kwd><kwd>hepcidin</kwd><kwd>interleukin 6</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Roemhild K, von Maltzahn F, Weiskirchen R, Knüchel R, von Stillfried S, Lammers T. Iron metabolism: Pathophysiology and pharmacology. Trends Pharmacol Sci. 2021;42(8):640–656. doi: 10.1016/ j.tips.2021.05.001</mixed-citation><mixed-citation xml:lang="en">Roemhild K, von Maltzahn F, Weiskirchen R, Knüchel R, von Stillfried S, Lammers T. Iron metabolism: Pathophysiology and pharmacology. Trends Pharmacol Sci. 2021;42(8):640–656. doi: 10.1016/ j.tips.2021.05.001</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rauf A, Shariati MA, Khalil AA, Bawazeer S, Heydari M, Plygun S, et al. Hepcidin, an overview of biochemical and clini - cal properties. Steroids. 2020;160:108661. doi: 10.1016/ j.steroids.2020.108661</mixed-citation><mixed-citation xml:lang="en">Rauf A, Shariati MA, Khalil AA, Bawazeer S, Heydari M, Plygun S, et al. Hepcidin, an overview of biochemical and clini - cal properties. Steroids. 2020;160:108661. doi: 10.1016/ j.steroids.2020.108661</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Олюнин ЮА, Лила АМ. Ревматоидный артрит: проблемы ремиссии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3):263–271.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Olyunin YuA, Lila AM. Rheumatoid arthritis: The problems of remission and therapy resistance. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2018;56(3): 263–271 (In Russ.)]. doi: 10.14412/1995-4484-2018-263-271</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Лила АМ. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16.</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: New opportunities and prospects. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2019;57(1):8–16 (In Russ.)]. doi: 10.14412/1995-4484-2019-8-16</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Галушко ЕА, Гордеев АВ, Матьянова ЕВ, Олюнин ЮА, Насонов ЕЛ. Труднолечимый ревматоидный артрит в реальной клинической практике. Предварительные результаты. Терапевтический архив. 2022;94(5):660-665.</mixed-citation><mixed-citation xml:lang="en">Galushko EA, Gordeev AV, Matyanova EV, Olyunin YA, Nasonov EL. Difficultto-treat rheumatoid arthritis in real clinical practice. Preliminary results. Terapevticheskii arkhiv. 2022;94(5):660–665 (In Russ.)]. doi: 10.26442/00403660.2022.05.201489</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40–50. doi: 10.1182/blood-2018-06-856500</mixed-citation><mixed-citation xml:lang="en">Weiss G, Ganz T, Goodnough LT. Anemia of inflammation. Blood. 2019;133(1):40–50. doi: 10.1182/blood-2018-06-856500</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Мазуров ВИ, Лила АМ. Особенности анемического синдрома у больных ревматоидным артритом и системной красной волчанкой. Медицинский академический журнал. 2001;1:58.</mixed-citation><mixed-citation xml:lang="en">Mazurov VI, Lila AM. Features of anemic syndrome in patients with rheumatoid arthritis and systemic lupus erythematosus. Medical Academic Journal. 2001;1:58 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Гордеев АВ, Галушко ЕА, Савушкина НМ, Демидова НВ, Семашко АС. Оценка мультиморбидного профиля (CIRS) при ревматоидном артрите. Первые результаты. Современная ревматология. 2019;13(3):10–16.</mixed-citation><mixed-citation xml:lang="en">Gordeev AV, Galushko EA, Savushkina NM, Demidova NV, Semashko AS. Assessing the multimorbid profile (CIRS) in rheumatoid arthritis. First results. Modern Rheumatology Journal. 2019;13(3):10–16 (In Russ.). doi: 10.14412/1996-7012-2019-3-10-16</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Weiss G. Anemia of chronic disorders: New diagnostic tools and new treatment strategies. Semin Hematol. 2015;52(4):313–320. doi: 10.1053/j.seminhematol.2015.07.004</mixed-citation><mixed-citation xml:lang="en">Weiss G. Anemia of chronic disorders: New diagnostic tools and new treatment strategies. Semin Hematol. 2015;52(4):313–320. doi: 10.1053/j.seminhematol.2015.07.004</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al.; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50(4):1051–1065. doi: 10.1002/art.20159</mixed-citation><mixed-citation xml:lang="en">Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al.; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50(4):1051–1065. doi: 10.1002/art.20159</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Галушко ЕА, Беленький ДА. Современные аспекты диагностики и лечения анемии у больных ревматоидным артритом. Научно-практическая ревматология. 2012;50(5):98–105</mixed-citation><mixed-citation xml:lang="en">Galushko EA, Belenkiy DA. Modern aspects of diagnosis and treatment of anemia in rheumatoid arthritis patients. Nauchno- Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2012;50(5):98–105 (In Russ.). doi: 10.14412/1995-4484-2012-1189</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Lanser L, Fuchs D, Kurz K, Weiss G. Physiology and inflammation driven pathophysiology of iron homeostasis-mechanistic insights into anemia of inflammation and its treatment. Nutrients. 2021;13(11):3732. doi: 10.3390/nu13113732</mixed-citation><mixed-citation xml:lang="en">Lanser L, Fuchs D, Kurz K, Weiss G. Physiology and inflammation driven pathophysiology of iron homeostasis-mechanistic insights into anemia of inflammation and its treatment. Nutrients. 2021;13(11):3732. doi: 10.3390/nu13113732</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Насонов ЕЛ, Лила АМ. Ингибиция интерлейкина 6 при иммуновоспалительных ревматических заболеваниях: достижения, перспективы и надежды. Научно-практическая ревматология. 2017;55(6):590-599</mixed-citation><mixed-citation xml:lang="en">Nasonov EL, Lila AM. Inhibition of interleukin 6 in immune inflammatory rheumatic diseases: Achievements, prospects, and hopes. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2017;55(6):590–599 (In Russ.) doi: 10.14412/1995-4484-2017-590-599</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Grillo AS, SantaMaria AM, Kafina MD, Cioffi AG, Huston NC, Han M, et al. Restored iron transport by a small molecule promotes absorption and hemoglobinization in animals. Science. 2017;356(6338):608–616. doi: 10.1126/science.aah3862</mixed-citation><mixed-citation xml:lang="en">Grillo AS, SantaMaria AM, Kafina MD, Cioffi AG, Huston NC, Han M, et al. Restored iron transport by a small molecule promotes absorption and hemoglobinization in animals. Science. 2017;356(6338):608–616. doi: 10.1126/science.aah3862</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Petzer V, Theurl I, Weiss G. Established and emerging concepts to treat imbalances of iron homeostasis in inflammatory diseases. Pharmaceuticals (Basel). 2018;11(4):135. doi: 10.3390/ph11040135</mixed-citation><mixed-citation xml:lang="en">Petzer V, Theurl I, Weiss G. Established and emerging concepts to treat imbalances of iron homeostasis in inflammatory diseases. Pharmaceuticals (Basel). 2018;11(4):135. doi: 10.3390/ph11040135</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10:9–17.</mixed-citation><mixed-citation xml:lang="en">Dixon SJ, Stockwell BR. The role of iron and reactive oxygen species in cell death. Nat Chem Biol. 2014;10:9–17.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93:1721-1741.</mixed-citation><mixed-citation xml:lang="en">Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93:1721-1741.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007;117(7):1933–1939. doi: 10.1172/JCI31342</mixed-citation><mixed-citation xml:lang="en">Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY. Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest. 2007;117(7):1933–1939. doi: 10.1172/JCI31342</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276(11):7811–7819. doi: 10.1074/jbc.M008923200</mixed-citation><mixed-citation xml:lang="en">Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem. 2001;276(11):7811–7819. doi: 10.1074/jbc.M008923200</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Muckenthaler MU, Rivella S, Hentze MW, Galy B. A red carpet for iron metabolism. Cell. 2017;168:344–361. doi: 10.1016/ j.cell.2016.12.034</mixed-citation><mixed-citation xml:lang="en">Muckenthaler MU, Rivella S, Hentze MW, Galy B. A red carpet for iron metabolism. Cell. 2017;168:344–361. doi: 10.1016/ j.cell.2016.12.034</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–2093. doi: 10.1126/science.1104742</mixed-citation><mixed-citation xml:lang="en">Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090–2093. doi: 10.1126/science.1104742</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Fillebeen C, Wilkinson N, Charlebois E, Katsarou A, Wagner J, Pantopoulos K. Hepcidin-mediated hypoferremic response to acute inflammation requires a threshold of Bmp6/Hjv/Smad signaling. Blood. 2018;132(17):1829–1841. doi: 10.1182/blood-2018- 03-841197</mixed-citation><mixed-citation xml:lang="en">Fillebeen C, Wilkinson N, Charlebois E, Katsarou A, Wagner J, Pantopoulos K. Hepcidin-mediated hypoferremic response to acute inflammation requires a threshold of Bmp6/Hjv/Smad signaling. Blood. 2018;132(17):1829–1841. doi: 10.1182/blood-2018- 03-841197</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Canali S, Zumbrennen-Bullough KB, Core AB, Wang CY, Nairz M, Bouley R, et al. Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice. Blood. 2017;129(4):405–414. doi: 10.1182/blood-2016-06-721571</mixed-citation><mixed-citation xml:lang="en">Canali S, Zumbrennen-Bullough KB, Core AB, Wang CY, Nairz M, Bouley R, et al. Endothelial cells produce bone morphogenetic protein 6 required for iron homeostasis in mice. Blood. 2017;129(4):405–414. doi: 10.1182/blood-2016-06-721571</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Mastrogiannaki M, Matak P, Mathieu JR, Delga S, Mayeux P, Vaulont S, et al. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica. 2012;97(6):827– 834. doi: 10.3324/haematol.2011.056119</mixed-citation><mixed-citation xml:lang="en">Mastrogiannaki M, Matak P, Mathieu JR, Delga S, Mayeux P, Vaulont S, et al. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica. 2012;97(6):827– 834. doi: 10.3324/haematol.2011.056119</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor M, Qu A, Anderson ER, Matsubara T, Martin A, Gonzalez FJ, et al. Hypoxia-inducible factor-2α mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. Gastroenterology. 2011;140(7):2044–2055. doi: 10.1053/ j.gastro.2011.03.007</mixed-citation><mixed-citation xml:lang="en">Taylor M, Qu A, Anderson ER, Matsubara T, Martin A, Gonzalez FJ, et al. Hypoxia-inducible factor-2α mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice. Gastroenterology. 2011;140(7):2044–2055. doi: 10.1053/ j.gastro.2011.03.007</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832–1843. doi: 10.1056/NEJMra1401038</mixed-citation><mixed-citation xml:lang="en">Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015;372(19):1832–1843. doi: 10.1056/NEJMra1401038</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Sankaran VG, Weiss MJ. Anemia: Progress in molecular mechanisms and therapies. Nat Med. 2015;21(3):221-230. doi: 10.1038/ nm.3814</mixed-citation><mixed-citation xml:lang="en">Sankaran VG, Weiss MJ. Anemia: Progress in molecular mechanisms and therapies. Nat Med. 2015;21(3):221-230. doi: 10.1038/ nm.3814</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007;109(1):353–358. doi: 10.1182/blood-2006-07-033969</mixed-citation><mixed-citation xml:lang="en">Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood. 2007;109(1):353–358. doi: 10.1182/blood-2006-07-033969</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Cavezzi A, Menicagli R, Troiani E, Corrao S. COVID-19, cation dysmetabolism, sialic acid, CD147, ACE2, viroporins, hepcidin and ferroptosis: A possible unifying hypothesis. F1000Res. 2022;11:102. doi: 10.12688/f1000research.108667.2</mixed-citation><mixed-citation xml:lang="en">Cavezzi A, Menicagli R, Troiani E, Corrao S. COVID-19, cation dysmetabolism, sialic acid, CD147, ACE2, viroporins, hepcidin and ferroptosis: A possible unifying hypothesis. F1000Res. 2022;11:102. doi: 10.12688/f1000research.108667.2</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
